Cerebrospinal Fluid Leak Repaired with Nasoseptal Flap in a 2-Week-Old Neonate
GPC2 MAY BE AN IMMUNOTHERAPEUTIC TARGET IN HIGH-RISK NEUROBLASTOMA
Plain-language medical vocabulary for precision diagnosis
LGG-57. Functional Characterization and Effective Targeting of NRF1-BRAF and ATG7-RAF1 Fusions Identified in Anaplastic Pleomorphic Xanthoastrocytoma Patients Without BRAF p. V600E MUTATION
HGG-40. HIGH GRADE GLIOMA CELL LINE COHORT AS AN EXAMPLE OF CHILDREN’S BRAIN TUMOR TISSUE CONSORTIUM TUMOR SPECIMEN PROCESSING PIPELINE
Pediatric low-grade gliomas with CRAF fusions respond differentially to targeted therapeutics based on their dimerization profiles
Recent studies have identified QKI-RAF1 and SRGAP3-RAF1 as CRAF (or RAF1) fusions in pediatric low-grade gliomas (PLGGs). CRAF fusions, like BRAF fusions are activating mutations driving the mitogen…
Comprehensive Analysis of Hypermutation in Human Cancer
We present an extensive assessment of mutation burden through sequencing analysis of >81,000 tumors from pediatric and adult patients, including tumors with hypermutation caused by chemotherapy, carcinogens, or…
Overcoming Resistance to Single-agent Therapy for Oncogenic BRAF Gene Fusions via Combinatorial Targeting of MAPK and PI3K/mTOR Signaling Pathways
Pediatric low-grade gliomas (PLGGs) are frequently associated with activating BRAF gene fusions, such as KIAA1549-BRAF, that aberrantly drive the mitogen activated protein kinase (MAPK) pathway. Although RAF inhibitors (RAFi) have…
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases….
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
We developed an RNA-sequencing-based pipeline to discover differentially expressed cell-surface molecules in neuroblastoma that meet criteria for optimal immunotherapeutic target safety and efficacy. Here, we show that GPC2…